Navigation Links
Perdue Kidd & Vickery Wins First Humira Trial - Abbott Laboratories To Pay $2.24 Million
Date:5/9/2013

CHICAGO, May 9, 2013 /PRNewswire/ -- Today, a Cook County jury entered a verdict finding Abbott Laboratories negligent and ordering it to pay $2,244,063.20 to Plaintiff Milton Tietz on behalf of his wife, Delores Tietz . The court entered judgment in that sum, plus costs, in favor of the Plaintiff.  This is the first Humira lawsuit filed against Abbott to go to trial.

"Humira has dangerous side effects and Abbott was negligent regarding them.  Justice has been done," said Tietz attorney Andy Vickery of Perdue Kidd & Vickery.

"We are honored that a jury of twelve people looked at the evidence and agreed that Abbott failed to do what the law requires," said Tietz attorney Jim M. Perdue, Jr.    

Delores Tietz was prescribed Humira, a TNF Blocker, for rheumatoid arthritis in October 2009 and took the drug for close to seven months, before almost dying. In early May 2010, Delores began experiencing chest pain and fevers.  Her illness went undiagnosed for weeks, and her family was told it was probable that she would not survive.  Finally, doctors diagnosed her with Humira-induced disseminated histoplasmosis, a severe, life-threatening infection. 

The FDA issued an alert in September 2008 to all manufacturers of TNF blockers, including Abbott Laboratories, to provide new information to the medical community about the risks of unrecognized, drug-induced histoplasmosis.  Abbott failed to send a letter directly to physicians warning of the danger until May 17, 2010, 20 months after the initial FDA alert and 10 days after Mrs. Tietz was hospitalized.  The jury found that Abbott was negligent for not taking reasonable measures to make sure Delores' doctors had a high index of suspicion for histoplasmosis. 

Milton Tietz is represented by Jim M. Perdue Jr. , Arnold Anderson Vickery and Fred Shepherd of Perdue Kidd & Vickery, and Gary D. McCallister of Gary D. McCallister & Associates LLC.

Perdue Kidd & Vickery is a national law firm of Personal Injury and Drug Injury Trial Lawyers.  The firm represents individuals and businesses across the country who have been harmed personally and financially.  Perdue Kidd & Vickery is based in Houston, Texas. For more information about Perdue Kidd & Vickery, visit www.perduekiddvickery.com or call 713-520-2500.    


'/>"/>
SOURCE Perdue Kidd & Vickery
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
2. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
3. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
4. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
5. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
8. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
9. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
10. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
11. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... England , April 24, 2017 ... development, today announced the addition of a major ... ,Validated In-situ Plate Seeding,). The VIPS has been ... and 384 well microplates as part of the ... system offers a simple and more reliable solution ...
(Date:4/20/2017)... April 20, 2017 Research and ... Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through ... their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production ... an in-depth assessment of the current trends in the ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
Breaking Medicine Technology:
(Date:4/24/2017)... , ... April 24, 2017 , ... ... they are seeking public support to bring their novel lifesaving device for the ... device packed with medical-grade sensors, specially designed to read a child’s vital signs, ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... opioid overdose deaths now claim the lives of 62 Americans each day.(1) Yet ... against drug manufacturers, distributors, pharmacies and prescribers by more than half.(2) Novus ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... health of individuals with HIV because it is not known to have significant ... have favorable effects to both lower cholesterol levels and dampen inflammation in the ...
(Date:4/24/2017)... ... ... Donna Parker, L. Ac. reads all sorts of books on self-improvement ... very practical. She wanted to write a guide/workbook that would give readers step-by-step guidance ... her in writing “ A Clear Path to a Vibrant Life : 7 Simple ...
(Date:4/24/2017)... ... ... “The Saint with Trin, and Omega Station”: a triple feature offering nonstop ... published author, Chris Jackson. Chris Jackson grew up in Abilene, Texas. He ... District teaching English. He is heavily involved in the youth group of his local ...
Breaking Medicine News(10 mins):